Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sreya Biswas"'
Autor:
Nina Derby, Sreya Biswas, Sofiya Yusova, Cristina Luevano-Santos, Maria Cristina Pacheco, Kimberly A. Meyer, Brooke I. Johnson, Miranda Fischer, Katherine A. Fancher, Cole Fisher, Yohannes M. Abraham, Conor J. McMahon, Savannah S. Lutz, Jeremy V. Smedley, Benjamin J. Burwitz, Donald L. Sodora
Publikováno v:
Viruses, Vol 16, Iss 2, p 296 (2024)
Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a major cause of morbidity and mortality in HIV-infected individuals, even those receiving optimal antiretroviral therapy. Here, we utilized the SIV rhesus macaque model and advanced lap
Externí odkaz:
https://doaj.org/article/cf243f8ab54e4cc8859bf12d3cd45809
Autor:
Sreya Biswas, Lauren N. Rust, Jochen M. Wettengel, Sofiya Yusova, Miranda Fischer, Julien N. Carson, Josie Johnson, Lei Wei, Trason Thode, Mohan R. Kaadige, Sunil Sharma, Majd Agbaria, Benjamin N. Bimber, Thomas Tu, Ulrike Protzer, Alexander Ploss, Jeremy V. Smedley, Gershon Golomb, Jonah B. Sacha, Benjamin J. Burwitz
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Here, Biswas et al. present and characterize a second-generation model of HBV infection in rhesus macaques, showing that extended infection requires suppression of host immunity.
Externí odkaz:
https://doaj.org/article/6626a89b33b1442db7ec196681607c1f
Autor:
Jochen M. Wettengel, Lea Hansen-Palmus, Sofiya Yusova, Lauren Rust, Sreya Biswas, Julien Carson, Junghyun Ryu, Benjamin N. Bimber, Jon D. Hennebold, Benjamin J. Burwitz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 8271 (2023)
CRISPR/Cas systems are some of the most promising tools for therapeutic genome editing. The use of these systems is contingent on the optimal designs of guides and homology-directed repair (HDR) templates. While this design can be achieved in silico,
Externí odkaz:
https://doaj.org/article/976b4f4f0f664076acc03b0527c5e3e0
Publikováno v:
Synthetic and Systems Biotechnology, Vol 1, Iss 1, Pp 34-38 (2016)
Thailanstatin A (TST-A) is a potent antiproliferative natural product discovered by our group from Burkholderia thailandensis MSMB43 through a genome-guided approach. The limited supply of TST-A, due to its low titer in bacterial fermentation, modest
Externí odkaz:
https://doaj.org/article/0f3402a9bfca48f9a1530e1c1edfad9c
Autor:
Michael J. Ricciardi, Lauren N. Rust, Nuria Pedreño-Lopez, Sofiya Yusova, Sreya Biswas, Gabriela M. Webb, Lucas Gonzalez-Nieto, Thomas B. Voigt, Johan J. Louw, Fernanda D. Laurino, John R. DiBello, Hans-Peter Raué, Aaron M. Barber-Axthelm, Kimberly Chun, Samantha Uttke, Lidiane M. S. Raphael, Aaron Yrizarry-Medina, Brandon C. Rosen, Rebecca Agnor, Lina Gao, Caralyn Labriola, Michael Axthelm, Jeremy Smedley, Justin G. Julander, Myrna C. Bonaldo, Laura M. Walker, Ilhem Messaoudi, Mark K. Slifka, Dennis R. Burton, Esper G. Kallas, Jonah B. Sacha, David I. Watkins, Benjamin J. Burwitz
Publikováno v:
Science Translational Medicine. 15
Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distri
Autor:
Jawad B. Belayet, Sarah Beamish, Mizzanoor Rahaman, Samer Alanani, Rajdeep S. Virdi, David N. Frick, A. F. M. Towheedur Rahman, Joseph S. Ulicki, Sreya Biswas, Leggy A. Arnold, M. S. Rashid Roni, Eric Y. Cheng, Douglas A. Steeber, Karyn M. Frick, M. Mahmun Hossain
Publikováno v:
J Med Chem
Histone acetylation is a prominent epigenetic modification linked to the memory loss symptoms associated with neurodegenerative disease. The use of existing histone deacetylase inhibitor (HDACi) drugs for treatment is precluded by their weak blood–
Autor:
Michael J. Ricciardi, Lauren N. Rust, Nuria Pedreño-Lopez, Sofiya Yusova, Sreya Biswas, Gabriela M. Webb, Lucas Gonsales-Nieto, Thomas B. Voigt, Johan J. Louw, Fernanda D. Laurino, John R. DiBello, Hans-Peter Raué, Aaron M. Barber-Axthelm, Samantha Uttke, Lidiane M.S. Raphael, Aaron Yrizarry-Medina, Brandon C. Rosen, Rebecca Agnor, Lina Gao, Caralyn Labriola, Michael Axthelm, Jeremy Smedley, Justin G. Julander, Myrna C. Bonaldo, Laura M. Walker, Ilhem Messaoudi, Mark K. Slifka, Dennis R. Burton, Esper G. Kallas, Jonah B. Sacha, David I. Watkins, Benjamin J. Burwitz
Few countermeasures to treat Yellow Fever virus (YFV) infection are under development, because vaccines have helped to limit new infections. Unfortunately, vaccine hesitancy, supply deficits, and a paucity of therapeutic options have left individuals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fa4d1d328a3f529ccebe44e7c8a358e
https://doi.org/10.1101/2022.05.16.491863
https://doi.org/10.1101/2022.05.16.491863
Autor:
Patrick K Hashiguchi, Jason S. Reed, Sreya Biswas, Scott G. Hansen, Louis J. Picker, Jonah B. Sacha, Roxanne M. Gilbride, Klaus Früh, Christine Meyer, Michael K. Axthelm, Helen L. Wu, Jennie Womack, Benjamin J. Burwitz, Mandana Mansouri
Publikováno v:
The Journal of Immunology. 204:2169-2176
Currently 247 million people are living with chronic hepatitis B virus infection (CHB), and the development of novel curative treatments is urgently needed. Immunotherapy is an attractive approach to treat CHB, yet therapeutic approaches to augment t
Autor:
Nina R Derby, Katherine A Fancher, Sreya Biswas, Sofiya Yusova, Cristina Luevano-Santos, Jeremy Smedley, Cristina Pacheco, Benjamin Burwitz, Donald L Sodora
Publikováno v:
The Journal of Immunology. 208:126.09-126.09
Non-alcoholic fatty liver disease (NAFLD) contributes to morbidity and mortality in HIV-infected individuals. To evaluate liver immune changes during SIV infection of macaques, we obtained liver biopsies laparoscopically at 2, 6, and 16 weeks post-in
Autor:
Benjamin J, Burwitz, Patrick K, Hashiguchi, Mandana, Mansouri, Christine, Meyer, Roxanne M, Gilbride, Sreya, Biswas, Jennie L, Womack, Jason S, Reed, Helen L, Wu, Michael K, Axthelm, Scott G, Hansen, Louis J, Picker, Klaus, Früh, Jonah B, Sacha
Publikováno v:
J Immunol
Currently 247 million people are living with chronic HBV infection (CHB), and the development of novel curative treatments is urgently needed. Immunotherapy is an attractive approach to treat CHB, yet therapeutic approaches to augment the endogenous